MY150820A - Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance - Google Patents
Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substanceInfo
- Publication number
- MY150820A MY150820A MYPI20102785A MY150820A MY 150820 A MY150820 A MY 150820A MY PI20102785 A MYPI20102785 A MY PI20102785A MY 150820 A MY150820 A MY 150820A
- Authority
- MY
- Malaysia
- Prior art keywords
- salt
- methyl ester
- acid methyl
- cysteic acid
- water soluble
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 3
- 239000013543 active substance Substances 0.000 title abstract 2
- 238000012377 drug delivery Methods 0.000 title abstract 2
- 125000002091 cationic group Chemical group 0.000 title 1
- -1 CYSTEIC ACID METHYL ESTER Chemical class 0.000 abstract 6
- XVOYSCVBGLVSOL-UHFFFAOYSA-N L-cysteine sulfonic acid Natural products OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 abstract 6
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SE2007/001128 WO2009078755A1 (en) | 2007-12-19 | 2007-12-19 | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY150820A true MY150820A (en) | 2014-02-28 |
Family
ID=40795733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20102785 MY150820A (en) | 2007-12-19 | 2008-12-18 | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8324274B2 (enExample) |
| EP (1) | EP2231193B1 (enExample) |
| JP (1) | JP5466174B2 (enExample) |
| KR (1) | KR101616135B1 (enExample) |
| CN (1) | CN101945671B (enExample) |
| AU (1) | AU2008339101B2 (enExample) |
| BR (1) | BRPI0821739B8 (enExample) |
| CA (1) | CA2709268C (enExample) |
| CY (1) | CY1121145T1 (enExample) |
| DK (1) | DK2231193T3 (enExample) |
| EA (1) | EA018559B1 (enExample) |
| ES (1) | ES2689509T3 (enExample) |
| HR (1) | HRP20181517T1 (enExample) |
| HU (1) | HUE039695T2 (enExample) |
| LT (1) | LT2231193T (enExample) |
| MX (1) | MX2010006906A (enExample) |
| MY (1) | MY150820A (enExample) |
| NZ (1) | NZ586858A (enExample) |
| PL (1) | PL2231193T3 (enExample) |
| PT (1) | PT2231193T (enExample) |
| SI (1) | SI2231193T1 (enExample) |
| WO (2) | WO2009078755A1 (enExample) |
| ZA (1) | ZA201004992B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009078756A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| WO2009078754A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
| CA2865011C (en) | 2012-02-29 | 2021-06-15 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
| CN112239418B (zh) * | 2019-07-18 | 2023-07-07 | 上海现代药物制剂工程研究中心有限公司 | 视黄醇类化合物及其钠盐的制备方法 |
| CN112321465B (zh) | 2019-07-18 | 2023-06-06 | 上海现代药物制剂工程研究中心有限公司 | 一种含苯基化合物、其中间体、制备方法及应用 |
| CN115212220A (zh) * | 2021-04-16 | 2022-10-21 | 上海现代药物制剂工程研究中心有限公司 | 一种药物递送系统及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197809B1 (en) * | 1998-12-23 | 2001-03-06 | Ardenia Investments Ltd. | Compounds for the treatment of cancer |
| HK1041889B (zh) * | 1999-03-11 | 2005-03-18 | 阿登尼亚投资有限公司 | 治疗癌症的新化合物 |
| US6656504B1 (en) | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| SE0101702D0 (sv) * | 2001-05-15 | 2001-05-15 | Ardenia Investments Ltd | Novel potentiating compounds |
| KR100566911B1 (ko) * | 2001-06-25 | 2006-04-03 | 주식회사 삼양사 | 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체 |
| US20050249786A1 (en) * | 2001-09-28 | 2005-11-10 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds |
| US20050191359A1 (en) | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
| JP2004010479A (ja) * | 2002-06-03 | 2004-01-15 | Japan Science & Technology Corp | ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法 |
| SE0202311D0 (sv) * | 2002-07-23 | 2002-07-23 | Ardenia Investments Ltd | Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment |
| JP2006199590A (ja) * | 2003-09-04 | 2006-08-03 | Nano Career Kk | 水溶性の塩基性薬物内包ナノ粒子含有組成物 |
| US20050196343A1 (en) * | 2004-02-27 | 2005-09-08 | Molecular Therapeutics, Inc. | Degradable nanoparticles |
| US8945629B2 (en) * | 2004-09-10 | 2015-02-03 | University Of Wyoming | Nanoparticles for cytoplasmic drug delivery to cancer cells |
| CN103169729A (zh) * | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| CN101291658B (zh) | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
| WO2009078756A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| WO2009078754A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
-
2007
- 2007-12-19 WO PCT/SE2007/001128 patent/WO2009078755A1/en not_active Ceased
-
2008
- 2008-12-18 EP EP08863195.7A patent/EP2231193B1/en active Active
- 2008-12-18 BR BRPI0821739A patent/BRPI0821739B8/pt not_active IP Right Cessation
- 2008-12-18 AU AU2008339101A patent/AU2008339101B2/en not_active Ceased
- 2008-12-18 KR KR1020107015634A patent/KR101616135B1/ko not_active Expired - Fee Related
- 2008-12-18 PT PT08863195T patent/PT2231193T/pt unknown
- 2008-12-18 CA CA2709268A patent/CA2709268C/en active Active
- 2008-12-18 MY MYPI20102785 patent/MY150820A/en unknown
- 2008-12-18 HR HRP20181517TT patent/HRP20181517T1/hr unknown
- 2008-12-18 EA EA201070626A patent/EA018559B1/ru unknown
- 2008-12-18 US US12/809,265 patent/US8324274B2/en active Active
- 2008-12-18 DK DK08863195.7T patent/DK2231193T3/en active
- 2008-12-18 CN CN2008801270941A patent/CN101945671B/zh not_active Expired - Fee Related
- 2008-12-18 JP JP2010539387A patent/JP5466174B2/ja not_active Expired - Fee Related
- 2008-12-18 HU HUE08863195A patent/HUE039695T2/hu unknown
- 2008-12-18 MX MX2010006906A patent/MX2010006906A/es active IP Right Grant
- 2008-12-18 LT LTEP08863195.7T patent/LT2231193T/lt unknown
- 2008-12-18 PL PL08863195T patent/PL2231193T3/pl unknown
- 2008-12-18 WO PCT/SE2008/051517 patent/WO2009078804A1/en not_active Ceased
- 2008-12-18 ES ES08863195.7T patent/ES2689509T3/es active Active
- 2008-12-18 SI SI200831998T patent/SI2231193T1/sl unknown
- 2008-12-18 NZ NZ586858A patent/NZ586858A/en not_active IP Right Cessation
-
2010
- 2010-07-14 ZA ZA2010/04992A patent/ZA201004992B/en unknown
-
2018
- 2018-10-03 CY CY20181101023T patent/CY1121145T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Varghese et al. | Cubosomes in cancer drug delivery: A review | |
| Han et al. | Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer | |
| Ghori et al. | Nasal drug delivery systems: an overview | |
| Illum | Nasal drug delivery—Recent developments and future prospects | |
| Khatoon et al. | Proniosomes derived niosomes: recent advancements in drug delivery and targeting | |
| Guan et al. | N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy | |
| MY157187A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
| GB0814302D0 (en) | Compounds and methods | |
| JP7568185B2 (ja) | アミノ酸ベースの栄養素の使用及びそれを含む医薬組成物 | |
| Schmitt et al. | Liposomal encapsulated curcumin effectively attenuates neuroinflammatory and reactive astrogliosis reactions in glia cells and organotypic brain slices | |
| CN107921033B (zh) | 供鼻内给药的格拉斯琼的生物粘着性组成物 | |
| WO2007040469A3 (en) | Chloroquine coupled compositions and methods for their synthesis | |
| CY1121145T1 (el) | Συστημα χορηγησης φαρμακων για χορηγηση μιας υδατοδιαλυτης, κατιοντικης και αμφιφιλης φαρμακευτικως ενεργης ουσιας | |
| JP2015034132A (ja) | 外用剤用組成物 | |
| Jin et al. | Mucoadhesive buccal tablet of leuprolide and its fatty acid conjugate: Design, in vitro evaluation and formulation strategies | |
| Singh et al. | Chitosan nanoparticles: a versatile frontier in drug delivery and wound healing across multiple routes | |
| CN104323985B (zh) | 一种基于碳材料的多糖类口服结肠靶向水凝胶的制备方法与应用 | |
| CN115916142A (zh) | 偶联萜烯缀合物 | |
| Jon et al. | Recent advances in donepezil delivery systems via the nose-to-brain pathway | |
| BRPI0821741B8 (pt) | sistema de liberação de droga para administração de uma substância anfifílica catiônica farmaceuticamente ativa compreendendo nanopartículas, composição farmacêutica, método de preparação de composição farmacêutica e seu uso | |
| Elmowafy et al. | Polysaccharide-based platforms for nasal delivery: design, features, and perspectives | |
| Hu et al. | Thioether choline phosphate liposomes for reactive oxygen species-trigger drug release | |
| Jain et al. | Phospholipid complex-based topical gel for codelivery of Erlotinib and Methotrexate in Psoriasis | |
| CN104490772A (zh) | 一种肝靶向紫杉醇纳米混悬剂及其制备方法 | |
| CN114010592B (zh) | 一种可瘤内或瘤周注射的咪喹莫特混悬液制剂及其制备方法和应用 |